Business Description

Description
Cubist Pharmaceuticals, Inc., was incorporated as a Delaware corporation in 1992. It is a biopharmaceutical company that provides research, development and commercialization of pharmaceutical products that address unmet medical needs in the acute care environment. Its products and product candidates are used, or are being developed to be used, in hospitals and other acute care settings, including home infusion and hospital outpatient clinics. Its currently marketed products include CUBICIN, DIFICID, and DIFICID. CUBICIN is a once-daily, bactericidal, I.V. antibiotic with activity against certain Gram-positive organisms, including MRSA. CUBICIN is approved in more than 50 countries including the U.S., EU, and Japan. DIFICID is a macrolide antibiotic for the treatment of CDAD. ENTEREG is an oral, peripherally-acting mu opioid receptor antagonist. The Company currently relies on a global network of third party contract manufacturers to manufacture its starting materials, active pharmaceutical ingredients, or APIs, and finished drug products for commercial sale. Its competitors include Abbott, Shionogi & Co., Ltd., Pfizer, Inc., King Pharmaceuticals, Inc., Wyeth Pharmaceuticals, Inc., Theravance, Inc., Forest Laboratories, Inc., ViroPharma Incorporated, among others. The Company's current and contemplated activities, and the products and processes that result from such activities, are subject to substantial government regulation.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 0.4
Equity-to-Asset 0.48
Debt-to-Equity 1.12
Debt-to-EBITDA 7.96
Interest Coverage 2.17
Piotroski F-Score 5/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.61
Distress
Grey
Safe
Beneish M-Score -2.5
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 3.54
Quick Ratio 3.29
Days Inventory 64.74
Days Sales Outstanding 36.08
Days Payable 32.61

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -2.8

Financials

FRA:CU6's 30-Y Financials
Income Statement Breakdown
No Enough Data
Balance Sheet Breakdown
No Enough Data
Cashflow Statement Breakdown
No Enough Data

Historical Operating Revenue by Business Segment

Historical Operating Revenue by Geographic Region

5-Step DuPont Analysis as of
No Enough Data

Guru Trades

See Details
To

Insider Trades

See Details
To

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To

Performance

Dividend
Log
Bar
To

Annualized Return %  

Symbol
1 Week
1 Month
3 Months
6 Months
YTD
1 Year
3 Years
5 Years
10 Years

Total Annual Return %  

Symbol
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015

Cubist Pharmaceuticals Inc Executives

Details

GF Value

Valuation Chart

Year:

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil €) 864.263
EPS (TTM) (€) 0.604
Beta 0
Volatility % 0
14-Day RSI 0
14-Day ATR (€) 0
20-Day SMA (€) 0
12-1 Month Momentum % 0
52-Week Range (€) 44.55 - 87.84
Shares Outstanding (Mil) 76.3

Piotroski F-Score Details

Year:
Component Result
Piotroski F-Score 5
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Cubist Pharmaceuticals Inc Filings

Filing Date Document Date Form
No Filing Data

Cubist Pharmaceuticals Inc Stock Events

Financials Calendars
Event Date Price(€)
No Event Data

Cubist Pharmaceuticals Inc Frequently Asked Questions

What is Cubist Pharmaceuticals Inc(FRA:CU6)'s stock price today?
The current price of FRA:CU6 is €87.58. The 52 week high of FRA:CU6 is €87.84 and 52 week low is €44.55.
When is next earnings date of Cubist Pharmaceuticals Inc(FRA:CU6)?
The next earnings date of Cubist Pharmaceuticals Inc(FRA:CU6) is .
Does Cubist Pharmaceuticals Inc(FRA:CU6) pay dividends? If so, how much?
Cubist Pharmaceuticals Inc(FRA:CU6) does not pay dividend.

Press Release

Subject Date
No Press Release